PROMISING NEW THERAPIES ON THE HORIZON

Dendreon is focused on discovering, developing and commercializing novel therapeutics to fight cancer. Our pipeline includes active cellular immunotherapy, monoclonal antibody and small molecule product candidates to treat a wide range of cancers.

The dedication of our research and development team has resulted in our lead product candidate, sipuleucel-T, rapidly approaching commercialization.

Sipuleucel-T, an active cellular immunotherapy, is in late-stage development for the treatment of metastatic, androgen-independent prostate cancer.

Lapuleucel-T, an active cellular immunotherapy, is in development for breast cancer, ovarian and colon cancer.

CEA, an active cellular immunotherapy, is in preclinical development for breast, lung and colon cancer.

CA-9, an active cellular immunotherapy, is in preclinical development for kidney, colon and cervical cancer.

Anti-Serine Protease Monoclonal Antibodies are in preclinical development for multiple cancers.

Trp-p8 (also known as Trp-M), a small molecule, is in preclinical development for lung, breast, prostate and colon cancer.